News
AMPH
44.05
+0.57%
0.25
Amphastar Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for AMPH
NASDAQ · 2h ago
Weekly Report: what happened at AMPH last week (1202-1206)?
Weekly Report · 9h ago
Weekly Report: what happened at AMPH last week (1125-1129)?
Weekly Report · 12/02 09:09
Here's Why Amphastar Pharmaceuticals (NASDAQ:AMPH) Has Caught The Eye Of Investors
Simply Wall St · 11/28 10:28
Weekly Report: what happened at AMPH last week (1118-1122)?
Weekly Report · 11/25 09:08
General Motors: A Top Pick On The Quant Dean's List
Seeking Alpha · 11/25 07:56
Amphastar Pharmaceuticals Initiated at Overweight by Wells Fargo
Dow Jones · 11/22 14:08
Amphastar Pharmaceuticals Price Target Announced at $55.00/Share by Wells Fargo
Dow Jones · 11/22 14:08
U.S. RESEARCH ROUNDUP- CPI Card Group, First Solar, Viking Therapeutics
Reuters · 11/22 07:35
Weekly Report: what happened at AMPH last week (1111-1115)?
Weekly Report · 11/18 09:08
Weekly Report: what happened at AMPH last week (1104-1108)?
Weekly Report · 11/11 09:09
Amphastar Pharmaceuticals, Inc.'s (NASDAQ:AMPH) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Simply Wall St · 11/09 13:31
Piper Sandler Reaffirms Their Buy Rating on Amphastar Pharmaceuticals (AMPH)
TipRanks · 11/07 11:42
Needham Remains a Hold on Amphastar Pharmaceuticals (AMPH)
TipRanks · 11/07 11:07
Amphastar Pharmaceuticals Reports Strong Q3 2024 Results
TipRanks · 11/07 04:58
Amphastar Pharmaceuticals Non-GAAP EPS of $0.96 misses by $0.02, revenue of $191.2M misses by $3.49M
Seeking Alpha · 11/06 22:55
AMPHASTAR PHARMACEUTICALS Q3 EPS USD 0.78
Reuters · 11/06 21:07
Here are the major earnings after the close today
Seeking Alpha · 11/06 15:00
Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates
NASDAQ · 11/05 00:35
Weekly Report: what happened at AMPH last week (1028-1101)?
Weekly Report · 11/04 09:09
More
Webull provides a variety of real-time AMPH stock news. You can receive the latest news about Amphastar Pharma through multiple platforms. This information may help you make smarter investment decisions.
About AMPH
Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. Its segments include finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets and distributes Primatene MIST, epinephrine, glucagon, phytonadione, lidocaine, enoxaparin, naloxone, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API for external customers and internal product development. Its pipeline has over 20 product candidates, including generic ANDAs, biosimilar, and others.